Günther, Kp, Lukas, C, Braun, J, Combe, B, Conaghan, P G, ...
OBJECTIVES: The European League Against Rheumatism (EULAR) and the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) have recognized the importance of variation in...
Zhang, W, Doherty, M, Leeb, BF, Alekseeva, L, Arden, NK, Bijlsma, JW, ...
Objectives: To develop evidence-based recommendations for the diagnosis of hand osteoarthritis (OA). Methods: The multidisciplinary guideline development group, representing 15 European countries,...
Bruyère, Olivier, Pavelka, K, Rovati, L C, Gatterova, J, Giacovelli, G, Olejarova, M, ...
OBJECTIVE: To assess the incidence of Total Joint Replacement (TJR) during the long-term follow-up of patients with knee osteoarthritis (OA) formerly receiving treatment with glucosamine sulphate or...
Gossec, L., Dougados, M., Phillips, C., Hammoudeh, M., De Vlam, K., Pavelka, K., ...
Background: Ten ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) were published in 2006. Objectives: (a) To disseminate and (b) to evaluate conceptual agreement with, and...
Zhang, W., Doherty, M., Leeb, B.F., Alekseeva, L., Arden, N.K., Bijlsma, J.W., ...
OBJECTIVES: To develop evidence based recommendations for the management of hand osteoarthritis (OA). METHODS: The multidisciplinary guideline development group comprised 16 rheumatologists, one...
ZHANG, W, DOHERTY, M, LEEB, BF, ALEKSEEVA, L, ARDEN, NK, BIJLSMA, JW, ...
Commentary: osteoarthritis of the knee and glucosamine (2006)
Altman, RD, Abramson, S, Bruyère, Olivier, Clegg, D, Herrero-Beaumont, G, Maheu, E, ...
Hanova, P., Pavelka, K., Dostal, C., Holcatova, I., Pikhart, H.
Objective: To estimate the annual incidence and prevalence of rheumatoid arthritis (RA), juvenile arthritis (JIA) and gout in a population based study in two regions of the Czech Republic with total...
Combe, B., Codreanu, C., Fiocco, U., Gaubitz, M., Kvien, T., ...
To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment.Methods: A double-blind,...
Combe, B., Codreanu, C., Fiocco, U., Gaubitz, M., Kvien, T., ...
To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment.Methods: A double-blind,...
Combe, B., Codreanu, C., Fiocco, U., Gaubitz, M., GEUSENS, Piet, Kvien, T., ...
To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment.Methods: A double-blind,...
ASAS/EULAR recommendations for the management of ankylosibg spondylitiis (2006)
Zochling, J, Burgos-Vargas, R, Collantes, E, Davis, JC, Dijkmans, B, ...
ASAS/EULAR recommendations for the management of ankylosing spondylitis. (2006)
Zochling, J, Burgos Vargas, R, Collantes, E, Davis, J C, Dijkmans, B, ...
OBJECTIVE: To develop evidence based recommendations for the management of ankylosing spondylitis (AS) as a combined effort of the 'ASsessment in AS' international working group and the European...
Strand, V., Balbir-Gurman, A., Pavelka, K., Emery, P., Li, N., Yin, M., ...
Objectives. To evaluate the long-term impact on physical function of a single course of rituximab in rheumatoid factor, seropositive patients with active rheumatoid arthritis (RA) despite ongoing...
Strand, V., Balbir-Gurman, A., Pavelka, K., Emery, P., Li, N., Yin, M., ...
Objectives. To evaluate the long-term impact on physical function of a single course of rituximab in rheumatoid factor, seropositive patients with active rheumatoid arthritis (RA) despite ongoing...
Strand, V., Balbir-Gurman, A., Pavelka, K., Emery, P., Li, N., Yin, M., ...
Objectives. To evaluate the long-term impact on physical function of a single course of rituximab in rheumatoid factor, seropositive patients with active rheumatoid arthritis (RA) despite ongoing...
Altman, RD, Abadie, E, Avouac, B, Bouvenot, G, Branco, J, Bruyère, Olivier, ...
Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to joint surgery as a potential therapeutic failure outcome...
Zhang, W., Doherty, M., Arden, N., Bannwarth, B., Bijlsma, J., ...
Objective: To develop evidence based recommendations for the management of hip osteoarthritis (OA). Methods: The multidisciplinary guideline development group comprised 18 rheumatologists, 4...
ZHANG, W, DOHERTY, M, ARDEN, N, BANNWARTH, B, BIJLSMA, J, GUNTHER, KP, ...
Pavelka, K, Senolt, L, Vilim, V, Spacek, P, Braun, M, Forejtova, S
No abstract available.
Jordan, K.M., Arden, N.K., Doherty, M., Bannwarth, B., Bijlsma, J.W., Dieppe, P., ...
Objectives: To update the EULAR recommendations for management of knee osteoarthritis (OA) by an evidence based medicine and expert opinion approach. Methods: The literature search and guidelines...
Codreanu, C, Combe, B, Fiocco, U, Gaubitz, M, Kvien, T, Pavelka, K, ...
Centrul Metodol Reumatol, Bucharest, Romania. Hop Lapeyronie, Serv ImmunoRhumatol, Montpellier, France. Polyclin Univ, Cattedra Reumatol, Azienda Clin Osped Padova, Padua, Italy. Polyclin Univ, Div...
Codreanu, C, Combe, B, Fiocco, U, Gaubitz, M, Kvien, T, Pavelka, K, ...
Centrul Metodol Reumatol, Bucharest, Romania. Hop Lapeyronie, Serv ImmunoRhumatol, Montpellier, France. Polyclin Univ, Cattedra Reumatol, Azienda Clin Osped Padova, Padua, Italy. Polyclin Univ, Div...
Pavelka, K., Recker, D. P., Verburg, K. M.
Objective. To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid...
Pavelka, K., Recker, D. P., Verburg, K. M.
Objective. To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid...
Pavelka, K., Recker, D. P., Verburg, K. M.
Objective. To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid...
Combe, BG, Codreanu, C, Fiocco, U, Gaubitz, M, Kvien, TK, Pavelka, K, ...
H Lapeyron, Montpellier, France. C Metod Reumat, Bucharest, Romania. Clin Osp, Padua, Italy. Univ Munster, D-4400 Munster, Germany. Limburgs Univ Ctr, Diepenbeek, Belgium. Dia Syk, Oslo, Norway. Inst...
Combe, BG, Codreanu, C, Fiocco, U, Gaubitz, M, Kvien, TK, Pavelka, K, ...
H Lapeyron, Montpellier, France. C Metod Reumat, Bucharest, Romania. Clin Osp, Padua, Italy. Univ Munster, D-4400 Munster, Germany. Limburgs Univ Ctr, Diepenbeek, Belgium. Dia Syk, Oslo, Norway. Inst...
PAVELKA, K., VOJTISEK, O., KANKOVÁ, D.
The side-effects which occurred in the course of 13 controlled trials of new nonsteroidal anti-inflammatory drugs are reviewed. Of 1643 patients treated, 185 (11%) reported adverse effects...
PAVELKA, K., SUSTA, A., VOJTÍSEK, O., BREMOVÁ, A., KANKOVÁ, D., HÁNDLOVÁ, D., ...
A comprehensive double-blind and double-blind cross-over study of the antiphlogistic and analgesic properties of ibuprofen, 300 mg. four times daily, and phenylbutazone, 150 mg. four times daily, is...
Pavelka, K, Sen, K P, Pelísková, Z, Vácha, J, Trnavský, K
A controlled, double blind, parallel group, long term study of hydroxychloroquine sulphate in the treatment of rheumatoid arthritis, comparing daily doses of 200 mg and 400 mg, is described. The...
Histological study of effects of colloidal 90 yttrium on knee joint tissues of rabbits.
Pavelka, K, Meier-Ruge, W, Müller, W, Fridrich, R
The administration of 0-2-0-4 mCi 90 yttrium (90Y) into a normal rabbit knee joint fails to induce medical synovectomy and results in the proliferation of the synovialis. The synovial mesothelium...
Effect of yttrium 90 on experimental allergic arthritis in rabbits.
Meier-Ruge, W, Müller, W, Pavelka, K
Seventeen rabbits were immunized with complete Freund's adjuvant and bovine serum albumin by the method of Dumonde and Glynn (1962), as modified by Cooke and Jasin (1972). Fifteen weeks after...
Pendleton, A, Arden, N, Dougados, M, Doherty, M, Bannwarth, B, Bijlsma, J, ...
BACKGROUND—Osteoarthritis (OA) is the most common joint disease encountered throughout Europe. A task force for the EULAR Standing Committee for Clinical Trials met in 1998 to determine the...
Jordan, K, Arden, N, Doherty, M, Bannwarth, B, Bijlsma, J, Dieppe, P, ...
Objectives: To update the EULAR recommendations for management of knee osteoarthritis (OA) by an evidence based medicine and expert opinion approach.
Van Holten, J, Pavelka, K, Vencovsky, J, Stahl, H, Rozman, B, Genovese, M, ...
Objective: To assess the efficacy of interferon beta (IFNß) in combination with methotrexate in treatment of patients with rheumatoid arthritis.
Zhang, W, Doherty, M, Arden, N, Bannwarth, B, Bijlsma, J, Gunther, K, ...
Objective: To develop evidence based recommendations for the management of hip osteoarthritis (OA).
Senolt, L, Braun, M, Olejarova, M, Forejtova, S, Gatterova, J, Pavelka, K
Background: Pentosidine, an advanced glycation end product, increasingly accumulates in articular cartilage with age, and contributes to the pathogenesis of osteoarthritis (OA). Increased...
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Zochling, J, Burgos‐Vargas, R, Collantes, E, Davis, J C, Dijkmans, B, ...
Combe, B, Codreanu, C, Fiocco, U, Gaubitz, M, Geusens, P P, Kvien, T K, ...